Opinion|Videos|February 28, 2025
Looking Ahead: Strategic Planning for Biosimilar Integration
A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How are you preparing for the increasing number of biosimilars entering the market?
- What changes to your biosimilar strategy do you anticipate making in the next 1 to 2 years?
- How do you see the role of biosimilars evolving at your institution and on a broader scale?
Advertisement
Related to this article
A review of 57 studies found music eases pain through positive emotion, control and moving in time with the beat, according to recent research out of Drexel University.
UC San Diego researchers found that early-onset metabolic dysfunction-associated steatotic liver disease cirrhosis was linked to higher genetic risk and Type 2 diabetes prevalence.
Behavior-informed care applies behavioral science principles to personalize support, including positive reinforcement and timely prompts.
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
Advertisement
Advertisement